Transporter Pharmacogenetics and Statin Toxicity

被引：235

作者：

Niemi, M. ^{[1
,2
]}

机构：

[1] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland

[2] Univ Helsinki, Cent Hosp, Helsinki, Finland

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷 / 01期

关键词：

POLYMORPHISM MARKEDLY AFFECTS; OATP-C SLC21A6; SLCO1B1; POLYMORPHISM; HEPATOBILIARY TRANSPORT; ABCB1; HAPLOTYPES; VARIANT ALLELES; PHARMACOKINETICS; PRAVASTATIN; PITAVASTATIN; ROSUVASTATIN;

D O I：

10.1038/clpt.2009.197

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Polymorphisms in transporter genes can have profound effects on statin pharmacokinetics. In particular, a common genetic variant of organic anion-transporting polypeptide 1B1 reduces the hepatic uptake of many statins, increasing the risk of statin-induced myopathy. Similarly, genetically impaired adenosine triphosphate (ATP)-binding cassette G2 transporter efflux activity results in a marked increase in systemic exposure to various statins. Importantly, the effects of these genetic polymorphisms differ depending on the specific statin that is used. This provides a rational basis for the individualization of lipid-lowering therapy.

引用

收藏

页码：130 / 133

页数：4

相关论文

共 33 条

[21]

Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936

[22] Effects of organic anion transporting polypeptide IBI haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril [J].

Maeda, Kazuya ;

Ieiri, Ichiro ;

Yasuda, Kuninobu ;

Fujino, Akiharu ;

Fujiwara, Hiroaki ;

Otsubo, Kenji ;

Hirano, Masaru ;

Watanabe, Takao ;

Kitamura, Yoshiaki ;

Kusuhara, Hiroyuki ;

Sugiyama, Yuichi .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (05) :427-439

[23] Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics [J].

Mwinyi, J ;

Johne, A ;

Bauer, S ;

Roots, I ;

Gerloff, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :415-421

[24] Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance [J].

Neuvonen, Pertti J. ;

Niemi, Mikko ;

Backman, Janne T. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) :565-581

[25] High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) [J].

Niemi, M ;

Schaeffeler, E ;

Lang, T ;

Fromm, MF ;

Neuvonen, M ;

Kyrklund, C ;

Backman, JT ;

Kerb, R ;

Schwab, M ;

Neuvonen, PJ ;

Eichelbaum, M ;

Kivistö, KT .

PHARMACOGENETICS, 2004, 14 (07) :429-440

[26] Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics [J].

Niemi, Mikko ;

Arnold, Katja A. ;

Backman, Janne T. ;

Pasanen, Marja K. ;

Goedtel-Armbrust, Ute ;

Wojnowski, Leszek ;

Zanger, Ulrich M. ;

Neuvonen, Pertti J. ;

Eichelbaum, Michel ;

Kivisto, Kari T. ;

Lang, Thomas .

PHARMACOGENETICS AND GENOMICS, 2006, 16 (11) :801-808

[27] SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin [J].

Niemi, Mikko ;

Pasanen, Marja K. ;

Neuvonen, Pertti J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (04) :356-366

[28] Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics [J].

Nishizato, Y ;

Ieiri, I ;

Suzuki, H ;

Kimura, M ;

Kawabata, K ;

Hirota, T ;

Takane, H ;

Irie, S ;

Kusuhara, H ;

Urasaki, Y ;

Urae, A ;

Higuchi, S ;

Otsubo, K ;

Sugiyama, Y .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :554-565

[29] Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin [J].

Pasanen, M. K. ;

Fredrikson, H. ;

Neuvonen, P. J. ;

Niemi, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (06) :726-733

[30] Global analysis of genetic variation in SLCOIB1 [J].

Pasanen, Marja K. ;

Neuvonen, Pertti J. ;

Niemi, Mikko .

PHARMACOGENOMICS, 2008, 9 (01) :19-33

← 1 2 3 4 →